Europe Monoclonal Antibodies Market size surpassed USD 44 billion in 2020 and is predicted to register a growth of over 13.3% from 2021 to 2027.
Growing prevalence of rare, infectious, and chronic diseases, will drive the product demand. For instance, in 2016, about 1.2 million people died due to cancer in EU-27 countries. As per the GLOBOCAN database 2020, the region accounts for around 22% of the total cancer cases worldwide. Significant portion of approved monoclonal antibodies are indicated for cancer treatment therapies.
Get more details on this report - Request Free Sample PDF
The manufacturers and innovative biopharmaceutical companies are progressively focusing on product development. Emphasis on product innovation has resulted in increasing number of approvals for several therapeutic applications including blood disorders, cancer, cardiovascular diseases autoimmune diseases, and infectious diseases, among others. For instance, in March 2021, Roche reported positive clinical outcomes in Phase III studies for its cocktail of investigational antibodies Casirivimab and Imdevimab that will reduce the risk of hospitalisation or death in COVID-19 patients. The approvals will further allow the company to expand studies to receive regulatory approval.
The incidence of COVID-19 is expected to have positive impact on monoclonal antibodies industry with its potential application in minimizing infection severity and risk of mortality. Industry players are continuously developing new mAb therapies in collaboration with private as well as government organization to reduce or eliminate mortality risk in COVID-19 patients.
Humanized mAbs segment revenue was around USD 14 billion in 2020. Numerous product launches and improved regulatory support will boost the segment growth. In addition, humanized monoclonal antibodies are approved for treatment of several therapeutic applications of cancer including breast cancer, lung cancer, melanoma, and stomach cancer, among others. Some humanized mAbs bind directly to the C-erB2 protein (HER2) that is considered as effective treatment of breast cancer.
Infectious disease segment is anticipated to expand at 14.1% CAGR during the forecast period. Rising incidence of various infectious diseases including the COVID-19 has augmented the product discovery and development of monoclonal antibody therapies. Over 50 monoclonal antibodies against SARS-CoV-2 are in development phase that will lead to launch of several products in near future.
Clinics held more than 18% market share in 2020. Increase in number of patient visits in these settings is contributing to high demand for therapeutic medicines. Further, the expanding network of clinics in developed as well as emerging economies broadens the accessibility and offers convenience to the patients. Moreover, awareness regarding innovative therapeutics among clinicians and presence of skilled personnel will contribute to segment revenue.
Germany monoclonal antibodies market accounted for 18% revenue share in 2020, attributed to business expansion of some leading industry players with strong product demand in the country. Along with disease prevalence, high treatment spending ability on advanced therapies will benefit the market size. Additionally, continuous technological advancements, improving accessibility and rising disposable income will influence the industry growth.
Some of the notable players involved in the Europe market include AbbVie Inc., Bristol Myers Squibb, Amgen, F. Hoffmann-La Roche, and Novartis AG.
These industry participants are undertaking various strategic initiatives to expand their geographic presence and product reach. For instance, in September 2020, Eli Lilly and Company announced collaboration with Amgen for expansion of antibody manufacturing and distribution capacity for COVID-19 therapies. This strategic alliance has helped the company to continue market distribution of its products.